dc.contributor.author
Casas-Méndez, Luis Fernando
dc.contributor.author
Abadías, María José
dc.contributor.author
Yuguero Torres, Oriol
dc.contributor.author
Bardés Robles, Ignasi
dc.contributor.author
Barbé Illa, Ferran
dc.contributor.author
Batlle Garcia, Jordi de
dc.date.accessioned
2024-12-05T22:01:11Z
dc.date.available
2024-12-05T22:01:11Z
dc.date.issued
2019-01-23T10:14:59Z
dc.date.issued
2019-01-23T10:14:59Z
dc.identifier
https://doi.org/10.1371/journal.pone.0208847
dc.identifier
http://hdl.handle.net/10459.1/65610
dc.identifier.uri
http://hdl.handle.net/10459.1/65610
dc.description.abstract
Introduction
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a common reason for presentation to emergency departments (ED), but the management of these episodes is often heterogeneous regardless of their potential impact on short-term adverse outcomes.
Methods This was a longitudinal, retrospective study of all patients>40 years old admitted to the ED of two Spanish teaching hospitals for an AECOPD between January 1st and May 31st, 2016. All data were collected from electronic medical records. The primary outcomes were patient treatment at discharge and 90-day mortality. Logistic regression was used to model the determinants of 90-day mortality.
Results
Of the 465 included patients, 56% were prescribed a 3-drug combination at hospital discharge, 22% a 2-drug combination, 19% a single drug, and 4% other or no treatment. Approximately 8% of patients died within 90 days after an AECOPD. Multivariate logistic models revealed that having more than 2 severe exacerbations within the last 12 months (OR (95% CI): 15.12 (4.22–54.22)) and being prescribed a single drug at discharge (OR (95% CI): 7.23 (2.44– 21.38)) were the main determinants of 90-day mortality after an AECOPD.
Conclusions
This study reflects the real-life heterogeneity in the pharmacological treatments prescribed after an ED admission for an AECOPD and suggests the potential impact of suboptimal inhaled treatment strategies on 90-day mortality rates.
dc.description.abstract
This research was supported by ALLER, Menarini Spain and GSK Spain. Jordi de Batlle acknowledges a research contract from Departament de Salut [PERIS 2016: SLT002/16/ 00364].
dc.publisher
Public Library of Science
dc.relation
Reproducció del document publicat a https://doi.org/10.1371/journal.pone.0208847
dc.relation
PLoS ONE, vol. 13, núm. 12, e0208847
dc.rights
cc-by (c) Fernando Casas et al., 2018
dc.rights
info:eu-repo/semantics/openAccess
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.title
Treatment strategies after acute exacerbations of chronic obstructive pulmonary disease: Impact on mortality
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion